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,1,3
Activator protein-1 (AP-1) is a dimeric transcription factor composed of the Jun, Fos and Atf families of proteins. Batf is
expressed in the immune system and participates in AP-1 dimers that modulate gene expression in response to a variety of
stimuli. Transgenic (Tg) mice overexpressing human BATF in T cells were generated using the human CD2 promoter
(CD2-HA(hemagglutininantigen)-BATF). By1yearofage,over90%ofthemicedevelopedalymphoproliferativedisorder(LPD).
TheenlargedlymphnodescharacteristicofthisLPDcontainapolyclonalaccumulationofTcellswithaCD4
þ bias,yeteffortsto
propagate these tumor cells in vitro demonstrate that they do not proliferate as well as wild-type CD4
þ T cells. Instead, the
accumulation of these cells is likely due to an apoptotic defect as CD2-HA-BATF Tg T cells challenged by trophic factor
withdrawal in vitro resist apoptosis and display a pro-survival pattern of Bcl-2 family protein expression. As elevated levels of
Batfexpressionareafeatureoflymphoidtumorsinbothhumansandmice,these observationssupporttheuseofCD2-HA-BATF
mice as a model for investigating the molecular details of apoptotic dysregulation in LPD.
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Activator protein-1 (AP-1) is a dimeric transcription factor that
is comprised of ubiquitous and tissue-speciﬁc basic leucine
zipper proteins of the Jun, Fos, Maf and Atf families of
proteins.
1 In response to many stimuli, AP-1 component
expression and DNA-binding activity are induced rapidly in
cells and result in both the positive and negative regulation of
gene expression.
2 In lymphocytes, AP-1 activity increases
following B-cell and T-cell receptor (TCR) engagement and
participates in a transcription factor network that regulates the
expression of genes associated with lymphocyte activation
and differentiation.
2,3 The AP-1 protein Batf is expressed in
both T and B cells and although there is compelling evidence
to suggest that AP-1 dimers in which Batf participates are
transcriptionally inactive,
4,5 the recent identiﬁcation of Batf
genetic targets in vivo indicates that Batf also may function as
a positive regulator of gene expression.
6,7 The role for Batf in
the development and differentiation of lymphocytes has been
investigated by several groups using T-cell-speciﬁc Batf
transgenic (Tg)
8,9 and systemic Batf knock-out mice.
6,7,10,11
Results show that increased expression of Batf in T cells
impacts signaling important to the proper development of
thymic NKT cells
8,9 and that the loss of Batf has a dramatic
impact on the differentiation of CD4
þ, IL–17-producing
T-helper cells (Th17) and T-follicular T-helper cells (Tfh) in
the periphery.
7,10 Additionally, Batf null animals possess an
intrinsic B-cell defect that cooperates with the Th17 and
Tfh-cell deﬁciencies to inhibit antibody responses to both
T-cell-dependent and T-cell-independent antigens.
6,10 In
conjunctionwiththesestudies,ananalysisofgeneexpression
changes in Batf null lymphocytes identiﬁed several genes in
T cells and B cells whose expression is correlated with the
bindingofBatftospeciﬁcgeneregulatoryregions.
6,7Precisely
how the Batf protein directs the transcription of these target
genes, however, is not known.
PreviousstudiesonthefunctionofBatfinvivohavefocused
primarily on phenotypes that are apparent in the mouse
immune system by 4 months of age. In this study, we have
utilized a line of Tg mice in which the human BATF protein is
expressed constitutively in both thymic and peripheral T cells
to test the impact of long-term, chronic BATF overexpression
(and AP-1 mis-regulation) on T-cell maturation and home-
ostasis. Remarkably, we found that by 12 months of age, the
vast majority of these animals develop lymphoid tumors
consisting of a polyclonal population of T cells. Our studies
demonstrate that this lymphoproliferative disorder (LPD) is
not associated with an increase in the proliferative capacity of
the T cells, but rather with an impaired response to an
apoptotic stimulus. Given the observation that increased
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www.nature.com/cddisBATF expression is a feature of secondary neoplasias in
human Hodgkin’s lymphoma
12 and of MuMLV-induced T-cell
lymphoma in mice,
13 the BATF Tg mice described herein
represent a useful model for investigating the role of AP-1
mis-regulation in LPD.
Results
Tg mice expressing hemagglutinin antigen (HA) -epitope
tagged human BATF protein in T cells (CD2-HA-BATF) have
been described previously in conjunction with a study that
demonstrated a direct role for BATF in regulating thymocyte
proliferation in vitro.
14 For the current study, it was important
to establish that the CD2-HA-BATF transgene continues to
be expressed in peripheral T cells and that TCR signaling in
Tg T cells remains intact and properly induced by AP-1
complexes containing BATF. Splenocytes from Tg, non-Tg
(WT) littermates and Batf null mice were stimulated in vitro
with anti-CD3 and anti-CD28 antibodies. Protein extracts
were prepared and immunblotted using anti-BATF antiserum.
Results show a robust overexpression of BATF protein in the
Tg cells (Figure 1a). Nuclear extracts were prepared from
resting and stimulated WT and Tg splenocytes and used for
electrophoretic mobility shift assays (EMSA) to detect the
presence of protein complexes competent for binding
consensus AP-1 DNA (Figure 1b). In the absence of
stimulation, the Tg nuclear extract showed increased AP-1
activity resulting from the formation of DNA-binding hetero-
dimers containing human BATF and the Jun proteins
expressed in resting T cells. Following stimulation, the
endogenous AP-1 factors, including Jun, Fos and Batf, are
upregulated in both WT and Tg cells and the DNA-binding
activity in these extracts increases accordingly. This DNA-
binding activity is identiﬁed as AP-1 by successful competition
with a 100-fold excess of unlabeled AP-1, but not SP-1, DNA.
The presence of BATF is demonstrated by the higher
molecular weight complexes detected following the addition
of polyclonal anti-BATF or monoclonal anti-HA antiserum to
the reaction (Figure 1b, complexes 1 and 2, respectively).
These results validate use of the Tg, CD2-HA-BATF mouse
model to study the long-term impact of BATF expression on
peripheral T-cell function.
Initial characterization of the effects of CD2-HA-BATF
expression on peripheral lymphoid tissues was performed
using histology and revealed a signiﬁcantly reduced area of
white pulp in Tg spleens (Figure 1c). This reduction was
quantiﬁedtorevealthatthetotalfollicleareainTgspleenswas
roughly 75% of WT controls (Figure 1c). To proﬁle the splenic
lymphocyte populations in CD2-HA-BATF mice, single-cell
suspensions from 8–12-week-old mice were analyzed by ﬂow
cytometry. Although the total cellularity of Tg spleens is
reduced compared with WT littermate controls (Figure 1d,
left panel), the percentage of T cells in the spleens of Tg mice
isincreased(Figure1d,centerpanel).Furthermore,TgTcells
show a statistically signiﬁcant bias toward CD4
þ cells
(Figure 1d, right panel). These ﬁndings are consistent with
the reduced percentage of splenic CD4
þ T cells noted
previously in Batf null (Batf
DZ/DZ) mice.
10
In order to determine how BATF overexpression inﬂuences
T-cell homeostasis, CD2-HA-BATF Tg mice, along with their
WT littermates, were allowed to age for up to 14 months.
A signiﬁcant decrease in body weight was observed in male
Tg mice, whereas the average weight of female Tg mice was
not reduced signiﬁcantly compared with WT controls
(Figure 2a). Upon necropsy, 91.6% of aged Tg mice of both
sexes exhibited gross peripheral lymphadenopathy in at least
onelymph node (Figure 2b).The affected nodes presented as
single or multiple discrete tumors. Mesenteric nodes were
most commonly affected by lymphadenopathy; however,
disease also was observed in other peripheral lymph nodes
and spleen. In addition to the gross lesions, microscopic
evidence of lymphoid inﬁltrate was detected in the liver and
pancreas of all tumor-bearing CD2-HA-BATF mice. Only
three WT mice showed signs of a similar gross and/or
microscopic disease at necropsy.
To evaluate the kinetics of tumor formation in CD2-HA-
BATF mice, a longitudinal magnetic resonance imaging (MRI)
study was conducted for 10 months during which time 11 Tg
and 10 WT littermate control mice were imaged monthly
beginning at 4 months of age. The results conﬁrmed that the
tumor phenotype was an exclusive feature of older Tg
animals, as the median age at earliest tumor detection by
this noninvasive method was 10 months (Figure 2c).
Histological characterization of the tumor tissue from
CD2-HA-BATF mice revealed a heterogeneous population
of small and intermediate sized lymphocytes, which comple-
tely disrupted the follicular architecture of the lymph
node (Figure 2d, upper panels). Immunohistochemistry
(IHC) identiﬁed the predominant tumor-cell population as
CD3
þ T cells although low, but variable, numbers of CD79a
þ
B cells were found throughout the affected nodes (Figure 2d,
middle panels). Importantly, the Tg HA-BATF protein was
detected in a high percentage of the tumor cells by IHC
(Figure 2d, lower panels) and ﬂow cytometry on individual
tumor-cell suspensions detected anti-HA reactive BATF
protein, on average, in 68% of the CD3
þ T cells analyzed
(Figure 2e).
To augment the IHC results, cell suspensions from several
tumors were analyzed using ﬂow cytometry to quantify the
relative percentages of B versus T lymphocytes and to
quantify any bias toward CD4
þ or CD8
þ cells. Pooled single-
cell suspensions from the lymph nodes of aged WT mice were
used as controls. As shown in Figure 3a, the tumors are
composed primarily of T cells (upper panels) and display a
bias towards CD4
þ cells (lower panels). Interestingly, the
CD4 and CD8 co-staining reveals a signiﬁcant level (B12%)
of an uncharacterized, double-negative (CD4
 CD8
 )
TCRb
þ cell type in these tumors. The presence of these
cells, together with both CD4
þ and CD8
þ single-positive T
cells, indicates that these tumors do not arise from a single
T-cellcloneaswouldbethecaseinT-celllymphoma.Toverify
the polyclonal origin of the T cells in these masses, a PCR-
based approach
15 was used to detect rearrangements within
the TCRb locus (Figure 3b). Three primers sets spanning
TCRb diversity (D) and junction (J) regions 1 and 2 were used
to amplify fragments of the locus from tumor DNA. Controls
included DNA representing the broad TCRb diversity
of thymocyte DNA, the clonal TCRb rearrangement from a
mouse iNKT cell line and the nonrecombined, germ line TCRb
locus in mouse ES cell DNA (Figure 3b). The genomic DNA
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Cell Death and Diseasefrom 15 individual tumors was analyzed and all samples
exhibited a polyclonal banding pattern similar to that oftumors
1, 2 and 3 presented in Figure 3b. These results conﬁrm the
polyclonal origin of the T cells that populate these lesions.
To investigate the mechanism underlying tumor formation
in CD2-HA-BATF Tg mice, single-cell suspensions of tumor
tissue were cultured in the presence of bromodeoxyuridine
(BrdU) and DNA replication quantiﬁed by enzyme-linked
immunosorbent assay (ELISA). Cells from the lymph nodes of
WT littermates were used as controls. Previous studies had
demonstrated that BATF expression inhibits the proliferation
ofTcellsinvitro
5,14andtheresultsshowninFigure3cconﬁrm
Figure1 CharacterizationoftheCD2-HA-BATFTgmice.(a)RepresentativeimmunoblotofproteinextractspreparedfromactivatedsplenicTcellsfromtheindicatedmice
– WT, CD2-HA-BATF (Tg) and Batf
DZ/DZ (null) – probed with anti-Batf antiserum (top) or with anti-b-actin antibody as a control (bottom). (b) Representative EMSA using a
radiolabelled AP-1 DNA probe and nuclear extracts from WT and CD2-HA-BATF (Tg) splenocytes stimulated in vitro with anti-CD3 and CD28 antibodies or with vehicle
(no stim) as a control. Competition with 100-fold molar excess of unlabeled AP-1, but not SP-1, consensus DNA identiﬁes the shifted complexes as AP-1. Addition of control
IgG anitibody (Ig cont.), anti-Batf antiserum (a-Batf) or anti-HA antiserum (a-HA) conﬁrms participation of Batf (endogenous and HA-tagged) in the complexes. Migration of
these antibody supershifted complexes varies with the antibody used and are indicated by the arrows (1 and 2) on the right. (c) Representative photomicrographs ( 4) of
H&E stained spleen sections reveala smallerwhite pulp area (arrows) in CD2-HA-BATF (Tg) versusWT mice(bars¼100mm). Cumulativedata fromsections in which white
pulpareawasmeasuredandexpressedasa percentofthetotalspleenareaare graphedbelow.(N¼4;*Po0.025).(d)FlowcytometrywasusedtoquantifyBandTcellsin
splenocytes prepared from CD2-HA-BATF (Tg) and WT mice. Left panel employs anti-TCRb and anti-B220 antibodies to quantify total T cells and B cells per spleen,
respectively (N¼8; *Po0.0008).Center panelexpresses thesesamedata asa percent of totalsplenoctyes (N¼8; *Po0.05).Right panelemploysanti-CD4andanti- CD8
antibodies to establish the percent of single-positive T cells (N¼8; *Po5 10
 7)
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Cell Death and Diseasethat Tg-tumor cells do not proliferate as well as WT controls.
These data provide convincing evidence that the LPD
detected in aged CD2-HA-BATF mice cannot be explained
by an increase in the proliferative capacity of the BATF-
expressing cells.
If the accumulation of T cells in these mice cannot be
attributed to increased proliferation, perhaps it is due to an
impairedapoptoticresponsethat,overtime,allowsTcellsthat
would normally be eliminated during the course of an adaptive
immune response to persist and accumulate in lymphoid
tissue. Toaddressthis hypothesis, puriﬁedCD4
þ T cellsfrom
the spleens of 8–12-week-old CD2-HA-BATF mice were
exposed to an apoptotic stimulus in vitro and the death
response of the culture was measured by the immunodetec-
tion of cleaved Pro-caspase 3. Initially, the response of the
cells to extrinsic apoptotic signals was examined and the
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Cell Death and Diseaseresults demonstrated that activation-induced cell death was
equivalent for Tg and WT T cells (data not shown).
Subsequently, an established in vitro protocol of cytokine
withdrawal
16 was used to compare the activated cell
autonomous death (ACAD)
17 response of WT versus Tg T
cells. In this case, under conditions of IL-2 withdrawal, the
presence of Caspase 3 was detected readily in control WT
cells within 24h. In contrast, there was dramatically less
Caspase 3 detected in lysates from Tg T cells, despite the fact
that these cells appear to express more Pro-caspase 3 than
their WT counterparts (Figure 3d). These data suggest that
overexpression of BATF impacts the T-cell gene expression
program in a manner that alters how T cells respond to
intrinsic apoptotic signals.
Further support for apoptotic suppression by BATF was
obtained using the terminal deoxynucleotidyl transferase
dUTP nick end-labeling (TUNEL) assay. CD4
þ cells were
isolated and apoptosis in control and in IL-2 depleted cultures
wasquantiﬁedafter24hbycountingcellsthatstainedpositive
for DNA strand breaks (Figure 4a). Assays were performed
using WT cells, CD2-HA-BATF cells and cells isolated from
Batf null mice. The cumulative data are presented in
Figure 4b. Using the level of apoptosis measured for Tg cells
following cytokine withdrawal as the baseline, WT cells
expressing a normal level of Batf show a 2-fold increase in
apoptosis and Batf null cells show a 4-fold increase. These
data suggest a putative function for Batf as a molecular
rheostat that determines the signal strength of apoptotic
induction during ACAD.
The apoptotic response of T cells to trophic factor with-
drawal relies on the differential expression of Bcl-2 family
proteins.
17–19 Notably, to coordinate the mitochondrial events
necessary to trigger Cytochrome c release and the subse-
quent activation of Caspases, transcriptional and post-
translational mechanisms are used to decrease the ratio of
the anti-apoptotic protein, Bcl-2, to the pro-apoptotic protein,
Bim.
20 To evaluate the impact of Batf on Bcl-2 and Bim
transcripts, WT, Tg and Batf null CD4
þ T cells were isolated
and gene expression changes captured in RNA prepared
before, and 12h following, IL-2 withdrawal. Semi-quantitative
PCR and RT-qPCR were performed to detect and to quantify
Bcl-2 and BimEL mRNA, respectively (Figure 4c). The
RT-qPCR results (Figure 4c, right panel) are graphed relative
to transcript levels in WT cells before IL-2 withdrawal which
were set to 1 (data not shown). Following IL-2 withdrawal, the
Tg cells do not fully downregulate Bcl-2 mRNA and,
accordingly, retain a low level of BimEL mRNA. Conversely,
while there is no statistical difference in the level of Bcl-2
mRNA in Batf null and WT cells, BimEL mRNA is 2-fold higher
in Batf null cells than in WT cells. These observations favor a
model in which Batf participates in nuclear events that
promote an anti-apoptotic gene expression program and
suppress the intrinsic, T-cell apoptotic response.
Discussion
This study describes a novel function for the AP-1 transcrip-
tion factor, Batf, as a mediator of nuclear events contributing
to the suppression of ACAD in CD4
þ T cells. We propose
that, over time, the resistance to apoptotic signaling conferred
on cells overexpressing Batf results in the accumulation
of T cells in lymphoid tissues of CD2-HA-BATF Tg mice.
The observation that the tumors arising in these mice are
polyclonal is consistent with this model and deﬁnes the
condition as T-cell LPD as opposed to T-cell lymphoma. The
etiology of the vast majority of human LPDs remains
unknown.
21 One exception is autoimmune lymphoprolifera-
tive syndrome (ALPS),
22 which is characterized by a defect in
the extrinsic (i.e., death receptor mediated) apoptotic path-
way. BATF drives formation of an LPD in mice by suppressing
theT-cellresponsetointrinsicapoptoticsignaling.Thisﬁnding
suggests an additional molecular mechanism that should
be investigated in the ongoing effort to further classify
human LPD.
As the name implies, ALPS presents as a polyclonal
accumulation of T cells and is associated with high levels of
autoantibody production.
22 In this regard, previous work with
Batf null mice revealed an immunoglobulin-deﬁcient pheno-
typeproducedasaconsequenceofcombineddefectsinTh17
and Tfh-cell development and in the mechanism of Ig class-
switch recombination.
10 It has been demonstrated that Batf
null mice are resistant to experimental autoimmune encepha-
lomyelitis (EAE)
7 and therefore, one might predict that EAE
would be accelerated in mice that overexpress Batf. Although
we have not examined this response in CD2-HA-BATF mice,
we have compared the resting levels of immunoglobulin in
sera from Tg mice and nontransgenic (WT) littermates.
Results show that all of the class-switched Ig subclasses
examined inthesemiceare increased 2–4fold(Figure 5a).To
investigate if self-reactive antibodies comprise a signiﬁcant
Figure 2 Gross characterization of CD2-HA-BATF Tg tumors. (a) WT and CD2-HA-BATF (Tg) mice were aged 10 to 12 months. Body weights in grams (g) were
determined at time of killing and the average weights plotted. Male Tg mice display a lower average body weight compared with WT males (N¼6; *Po0.03), whereas the
very modest decrease in the weight of female Tg (N¼9) versus WT (N¼8) mice is not signiﬁcant (P¼0.10). Bars represent S.E. (b) Mice of the indicated genotype, aged
10 to 12 months, were examined at necropsy for gross lesions. A typicaltumor (arrow) is shown with a mm ruler for size reference. Twenty-two of 24 (491%) CD2-HA-BATF
(Tg) mice demonstrated gross lesions together with peripheral lymphadenopathy in at least one node and microscopic lesions in liver and pancreas. Tumors were detected in
only three WT control mice (11%). (c) Eleven CD2-HA-BATF (Tg) and 10 WT mice were subject to MRI at monthly intervals starting at 4 months to monitor tumor formation.
A representative, T2 weighted MRI of a 10-month Tg mouse (left panel) highlights a discrete mesenteric lymph node tumor (circled in red) and the presence of splenomegaly
(arrow).ThekineticsoftumordetectioninTgandWTanimals(rightpanel)indicatethatthemedianageoftumoronsetinTgmice(dottedline)is10months.(d)Representative
photos of H&E stained sections contrast the normal architecture of a lymph node from a 10-month-old WT mouse (upper left) with the architecture of a lymphoid tumor
identiﬁedinanagedTgmouse(upperright).SerialsectionsofthesameTgtumor(visualizedusingHonly)wereprocessedforIHCandstainedwithanti-CD3todetectTcells,
anti-CD79a to detect B cells and anti-HA to detect the expression of the HA-BATF protein. The bottom right panel is the inset of the anti-HA IHC staining on the bottom left
(box).Imagesare  10 magniﬁcation (bar¼40mm) exceptfor theinsetimage whichis  40 (bar¼10mm). (e) Flowcytometrywasused toquantifythepercentTg-tumorT
cells expressing HA-BATF. Cells were stained with anti-CD3e and anti-HA antibodies. A representative histogram from cells gated on CD3e
þ cells shows that cells from the
tumor (black) are HA-positive relative to control cells (red). The average percent of HA-positive cells per tumor (N¼3) is indicated
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Cell Death and Diseaseportion of this serum Ig, anELISA for anti-nuclear antigenwas
performed.After normalizingfordifferencesintotalIgcontent,
more than a 2-fold increase in reactivity was detected in the
sera of CD2-HA-BATF Tg mice (Figure 5b). These data
correlate nicely with our observations in Batf
DZ/DZ mice
10 and
suggest that the Batf-induced alterations in T-cell home-
ostasis that lead to LPD also have a permissive effect on the
development of autoimmune disease. Subjecting CD2-HA-
BATF Tg mice to experimental models of immune-mediated
disease will be used as a further test of this possibility.
The ﬁndings from the present study and other descriptions
of elevated Batf expression in human and mouse peripheral
lymphoid tumors
12,13 suggest that the inﬂuence of Batf on
AP-1 activity and on the transcription of speciﬁc genes has a
role.ACAD,theapoptoticprocessthatisimpairedinCD2-HA-
BATF T cells, is associated with both transcriptional and post-
Figure 3 CD2-HA-BATF Tg-tumor T cells proliferate poorly and show reduced Pro-caspase 3 cleavage upon induction of ACAD. (a) Flow cytometry was used to analyze
cell suspensions from CD2-HA-BATF Tg-tumor tissue surface stained for B220, CD3e, CD4, and CD8. Quadrant numbers from the ﬂow plots and y axis values from
accompanyinggraphsindicatethepercentageofBversusTcells.CD2-HA-BATFTgtumors(N¼4)arecomposedprimarilyofTcells(*Po5 10
 5)withabiastowardsthe
CD4
þ population (*Po0.0004). Lymph node cell suspensions from age-matched, WT mice (N¼6) were used as controls. Bars denote S.E. (b) To assess tumor T-cell
clonality,PCRwasusedtoamplifythreeseparateregionsoftheTCRblocusD1-J2domain(upperdiagram)fromDNAisolatedfromTgtumors(Tumor1,2,3).Results(lower
panels)showabandingproﬁlecharacteristicof apolyclonalT-cellpopulation.ThymusDNA (Thy)isa controlfor allpossibleTCRb D–J rearrangementsandtheiNKTcellline
expressesasingleTCRbchain.ES129DNA(GL)demonstratesthegermline,nonrearrangedampliconwhichforDb1-Jb2isresolvedonaseparategelduetosize.M¼mol.
wt. markers of 1, 0.7, 0.5 and 0.3kbp. Fifteen independent tumor samples were analyzed with comparable results. (c) T cells within single-cell suspensions prepared from Tg
tumors or from the pooled peripheral lymph nodes of age-matched, WT mice were stimulated with anti-CD3 and anti-CD28 and evaluated for proliferation by measuring BrdU
uptake (N¼4, *Po0.005). Bars indicate S.E. (d) Anti-Caspase 3 immunoblot of lysates prepared from WT and Tg CD4
þ T cells following 24h of IL-2 withdrawal to induce
ACAD. Immunodetection of Hsp90 was used as the control. Lysates from two mice per genotype are shown. The experiment was performed four times with similar results
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Cell Death and Diseasetranslational events that increase the ratio of pro-apoptotic
(e.g.,Bim)toanti-apoptotic(e.g.,Bcl-2)proteinsand,bydoing
so, promote Cytochrome c release by mitochondria and the
activation of cytosolic pro-caspases.
17,18,23,24 The shift from
an anti- to a pro-apoptotic program in T cells occurs by a two-
step process. The ﬁrst step triggers Bcl-2 levels to decline as
result of changes in the cytokine environment
25 or increases
in reactive oxygen species (ROS).
26,27 Bcl-2 downregulation
is not sufﬁcient, however, and apoptosis requires a second
step that is mediated by an increase in Bim expression. As
prior studies demonstrate that BATF functions as an AP-1
inhibitor,
4,5 theinﬂuence ofBATFoverexpression ondecreas-
ing Bcl-2 levels is probably indirect. On the other hand, the
reduced level of the BimEL transcript in CD2-HA-BATF Tg
T cells and the dramatically elevated level of BimEL mRNA in
BatfnullcellsarebothconsistentwithadirectroleforBatfasa
negative regulator of Bim transcription. Interestingly, apopto-
sis following trophic factor withdrawal in neurons has been
shown to rely on the induction of Bim transcription by a c-Jun
containingAP-1complexthatbindsdirectlytoanAP-1motifin
the Bim promoter.
28,29 Furthermore, in hepatocytes, the
generation of ROS triggers apoptosis by promoting the Erk-
dependent induction of c-Fos and increased Bim transcription
through this same AP-1 site.
30 Batf is not expressed neurons
or hepatocytes making it worthwhile to identify the compo-
nents of the AP-1 complex that are responsible for upregulat-
ing BimEL mRNA in T cells and establishing how Batf may
alter the activity of this AP-1 complex to inhibit the induction of
Bim gene transcription during ACAD.
Our analysis of the Batf-associated apoptotic defect has
focused on CD4
þ T cells largely because of the CD4
þ T-cell
bias displayed by the tumors. However, this does not rule out
that apoptotic pathwaysin peripheral CD8
þ T cellsfrom CD2-
HA-BATF and Batf null mice also are affected. In fact, while
this work was in its ﬁnal stages, Kuroda et al.
11 published a
study in which WT and Batf null mice were used to establish a
Figure 4 Impaired intrinsic apoptotic signaling in CD2-HA-BATF T cells. (a) CD4
þ T cells from WT, CD2-HA-BATF (Tg), and Batf
DZ/DZ (null) mice were subjected to IL-2
withdrawal to induce ACAD. Representative photomicrographs of TUNEL staining ( 20) illustrate reduced apoptosis in Tg CD4
þ T cells and increased apoptosis in
Batf
DZ/DZ CD4
þ Tcells,respectively.(b)Theaverage%apoptoticcellsforeachgenotype(N¼11,WT;N¼6,Tg;N¼6,null)wascalculatedusingtheaveragesfromthree
ﬁelds (as shown in (a)) per slide per mouse (*Po0.02). Bars indicate S.E. (c) Key transcripts involved in ACAD were detected and quantiﬁed using RNA isolated from the
CD4
þ T cells of WT (N¼6), Tg (N¼6) and null (N¼6) mice before (þ) and after ( ) IL-2 withdrawal. The left panel is a representative gel showing the results from the
semi-quantitativePCRanalysisofBcl-2andBimELtranscriptlevelsintheRNAofonemousepergenotype.Detectionofb-actintranscriptsisusedasacontrol.Thepanelson
the right contain the cumulative results of RT-qPCR analysis of all mouse samples (six per genotype) and reveal the impact of different levels of Batf expression on Bcl-2 and
BimEL transcripts. For these experiments, detection of Hrpt mRNA was used as a control (*Po0.02). Bars indicate S.E.
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Cell Death and Diseaserole for Batf in the later stages of CD8
þ effector T-cell
differentiation and survival. In that study, Batf was shown to
haveapositiveimpactoncellularenergymetabolisminCD8
þ
T cells, largely by inhibiting expression of the histone
deacetylase Sirt1 which, in turn, allowed for the expression
of genes necessary for cell survival. At which stage the
expression of Batf might affect Sirt1 and the proper epigenetic
remodeling of loci critical to the function of CD4
þ T-cell
subsets is an interesting question. Also of interest are studies
to establish if the tumor cells in CD2-HA-BATF Tg mice reﬂect
a T-memory phenotype, which might be predicted based on
our results and those of Kuroda et al.
11
The mouse model described here provides novel opportu-
nities to investigate how mis-regulation of the AP-1 transcrip-
tion factor in T cells contributes to the improper control of
apoptotic pathways and to the development of LPD. The high
penetrance of this BATF-driven condition, together with the
ability to detect the onset of these tumors using noninvasive
MRI, should allow for testing both genetic strategies
and targeted therapeutics for their effectiveness against
T-cell LPD.
Materials and Methods
Mice. C57BL/6 CD2-HA-BATF and Batf
DZ/DZ mice have been described
previously
10,14 and were maintained in a speciﬁc-pathogen free animal facility
according to institutional guidelines. CD2-HA-BATF mice overexpress the human
BATF protein fused at the amino terminus to HA. The human and mouse BATF
proteins differ by ﬁve amino acids and all are conservative changes located
outside the core basic leucine zipper domain. Mice used in experiments were
between 8 and 12 weeks of age unless noted otherwise.
Histology and IHC. Tissues were processed for hematoxylin and eosin
(H&E) staining and IHC as described.
31 Sections were viewed using an
Olympus BX41 microscope (Olympus Corp., Center Valley, PA, USA) and
photographed using a Microimager II camera (Qimaging, Surrey, BC, Canada) and
Northern Eclipse software (EMPIX Imaging Inc., Mississauga, ON, Canada). The
comparison of spleen white pulp was made at  4 magniﬁcation using Image J
software (NIH, Bethesda, MD, USA) to circumscribe the areas of white pulp area
within the total area of spleen. White pulp area was expressed as a percentage of
total spleen area and was averaged from the analysis of four, independent
preparations per genotype. IHC was performed using the following primary
antibodies: anti-CD79a (clone# HM57, Dako, Carpinteria, CA, USA), rabbit anti-
human CD3 (Dako) and rat anti-HA (clone# 3F10, Roche, Indianapolis, IN, USA)
and signal-detection reagents from Vector Laboratories (Burlingame, CA, USA).
IHC images are  10 magniﬁcation, except for the inset which is  40. This IHC
panel was repeated for four different tumors with similar results.
Flow cytometry. Flow cytometry was performed using a FC500 cytometer
(Beckman Coulter, Brea, CA, USA) and the following antibodies from BD
Biosciences (San Diego, CA, USA): anti-TCRb (clone# H57-S97), anti-CD3e
(clone# 145-2C11), anti-B220 (clone# RA3-6B2), anti-CD4 (clone# L3T4) and
anti-CD8 (clone# 53-6.7). The anti-HA antibody (clone# 3F10) is from Roche.
Data were analyzed using FCSExpress3 software (DeNovo Software, Los
Angeles, CA, USA).
Clonality assay. Genomic DNA was isolated from 15 independent CD2-HA-
BATF tumors, the thymus tissue of a C57BL/6 mouse, ES 129 cells and 431A11
iNKT cells
32 using phenol/chloroform extraction and the Wizard DNA Clean-UP
System (Promega, Madison, WI, USA). The DNA samples were analyzed for D–J
rearrangements in the TCRb locus using the primers and ampliﬁcation conditions
described by Kawamoto et al.
15
Cell proliferation assay. DNA synthesis was measured using a BrdU Cell
Proliferation Assay Kit (Millipore, Billerica, MA, USA). Single-cell T-cell
suspensions were prepared from CD2-HA-BATF lymph node tumors and age-
matched, WT lymph nodes using CD19
þ B-cell depletion (Miltenyi Biotech,
Auburn, CA, USA). Cells were plated at 2 10
4cells/well in 96-well plates and
stimulated with anti-CD3 and anti-CD28 antibodies as described.
8 After 48h, BrdU
was added for 24h and labeled DNA quantiﬁed by ELISA.
Cytokine withdrawal experiments. Splenocytes were prepared
and CD4
þ T cells isolated using a CD4
þ T-cell isolation kit (Miltenyi Biotec,
Auburn, CA, USA). T-cell activation and cytokine withdrawal were performed as
described.
16 Brieﬂy, T cells were activated for 72h in 100U/ml IL-2 (R&D
Systems, Minneapolis, MN, USA), 5mg/ml soluble anti-CD28 and plate-bound
anti-CD3e (BD Biosciences). Following 24h of culture in IL-2 alone, the IL-2 was
withdrawn. Samples for immunoblot and cytospin preparations were collected 24h
post-withdrawal. RNA samples were harvested 12h post-withdrawal.
Immunoblots. To detect Batf protein, T cells were isolated from spleen,
stimulated with anti-CD3 and anti-CD28 antibodies as described
8 and
immunoblotted as described
33 using rabbit anti-BATF serum.
34 Reactivity with
anti-b-actin antibody was used as the positive control. For Pro-caspase 3 and
Capase 3, protein isolated from T cells that had been subjected to cytokine
withdrawal was immunoblotted using rabbit anti-Caspase 3 antibody (Cell
Signaling Technologies, Danvers, MA, USA). Detection of Hsp90 using rabbit anti-
Hsp 90 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as
the positive control.
MRI. A monthly, longitudinal MRI study was performed using 11 CD2-HA-BATF
mice and 10 sex-matched, WT littermates beginning at 4 month of age and ending
at 14 months of age. The animals were imaged while sedated with 70–90mg/kg
ketamine and 5–10mg/kg xylazine administered intraperitoneally. Images were
acquired using a 3.0 Tesla General Electric Signa HDx scanner and a transmit/
receive knee array coil (GE Healthcare, Piscataway, NJ, USA).
TUNEL assay. Splenocytes from 9 WT, 6 CD2-HA-BATF and 6
Batf
DZ/DZ mice were enriched for CD4
þ T cells by Macs (Miltenyi Biotech) and
subjected to cytokine withdrawal as described above. After 24h, cells were
transferred to slides using a CytoSpin 4 Cytocentrifuge (Thermo Fisher Scientiﬁc,
Waltham, MA, USA). TUNEL of apoptosis-induced DNA damage was assessed
using the In Situ Cell Death Detection Kit (Roche). TUNEL-positive cells were
expressed as a percent of total cells (DAPI positive) per ﬁeld at  20
magniﬁcation. Three ﬁelds per slide were counted and averaged to obtain the
percent apoptotic T cells for each mouse spleen.
Figure 5 Hypergammaglobulinemia in CD2-HA-BATF Tg mice is coupled with
indicators of autoimmune disease. (a) ELISA was performed on sera isolated from
WT and CD2-HA-BATF (Tg) mice to measure the relative levels of the indicated Ig
isotypes. The results from ﬁve mice per genotype were averaged for IgM, IgG1,
IgG2c and IgE; three mice per genotype were used for the averaged results for IgA
(*Po0.05). Bars indicate S.E. (b) ELISA was performed on sera isolated from WT
and Tg mice to assess levels of nuclear antigen-reactive antibodies. The average
(N¼3) is presented. (*Po0.008). Bars indicate S.E.
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Cell Death and DiseaseAnalysis of mRNA expression. Splenocytes were enriched for CD4
þ T
cells and subjected to cytokine withdrawal as described above. After 12h, RNA
was isolated and converted to cDNA. SYBR green (Roche) RT-qPCR was
performed and results analyzed as described.
10 Hprt and b-actin primers have
been described previously
10 and primers for Bcl-2 and BimEL are from Kuribara
et al.
35 Results were normalized to Hprt expression and DDCt values used to
calculate the relative expression level of each mRNA. Semi-quantitative RT-PCR
was performed as described
34 for 25 cycles using primers for b-actin,
34
Bcl-2
36)and BimEL.
35 DNA products were visualized by ethidium bromide staining
following resolution by 3% agarose gel electrophoresis.
ELISA. Blood from mice was collected by cardiac puncture and allowed to clot
at room temperature in Microtainer Serum Separator Tubes (BD Biosciences).
Serum was isolated by centrifugation. ELISA for the IgM, IgG1, IgG2C, IgA and
IgE isotypes were perfomed as previously described.
10 Values were normalized
and expressed as a fold-over the WT control, which was set to 1. ELISA for
anti-nuclear antibodies (ANA) was performed using the Mouse ANA Ig ELISA Kit
(Alpha Diagnostics, San Antonio, TX, USA). In this case, total protein content was
normalized by adding Ig to the non-Tg sera before assay. Values in units/ml were
calculated from a standard curve using the reagents provided in the kit.
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